|By PR Newswire||
|February 3, 2014 12:30 PM EST||
SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen is focused on developing two drug technology platforms: (i) ATMs as a safer and more effective alternative to taxane chemotherapy, and (ii) its proprietary platform of super-benzopyrans, a group of small molecules with high efficacy against the full breadth of cells within a tumor, including the cancer stem cells, which have been resistant to drugs and radiation up to this point.
Dr. Stehn will hold the position of Director, ATM Program, and will have full oversight over the progress of this technology into the clinic in 2015. Professor Gunning will join the Company's Scientific Advisory Panel for ATM Technology.
"I am extremely pleased to join Novogen at a crucial period in the company's development," said Dr. Stehn. "The work we have conducted thus far in understanding ATMs leads us to believe we may have discovered a new approach to cancer therapy that could potentially offer patients a safer and more effective alternative to traditional chemotherapy, but the commonly-used taxane drugs in particular. I look forward to transitioning my work in academic research to Novogen and joining a team that is dedicated to developing new cost-effective approaches to many of the most lethal forms of cancer."
Dr. Stehn and Professor Gunning made a significant breakthrough when they discovered that the microfilament components of the cytoskeleton of cancer cells are made up largely of a particular isoform of the protein tropomyosin known as Tm5NM1. Elimination of Tm5NM1 significantly impacted the growth and survival of the cancer cell without adversely effecting normal tissue.
The first generation of drug directed against this isoform resulted in a significant anti-tumor effect in animals with human tumor xenografts (melanoma, neuroblastoma), without the collateral toxicity seen with previous compounds targeting the actin microfilaments. Their work was featured on the cover of the August (2013) edition of the journal, Cancer Research.
"I've dedicated my life's work to researching the cytoskeleton and developing treatments for children afflicted with cancer. I'm excited to become a part of Novogen as the Company moves this promising technology into the clinic in neuroblastoma, the most prevalent solid tumor in children. It is a great bonus that these drugs are likely to be equally effective against adult cancers such melanoma, ovarian and prostate cancer," said Professor Gunning.
During 2014, Novogen expects to file up to four Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for its ATM technology, enabling the company to start clinical trials in 2015.
Prior to joining Novogen, Dr. Stehn was Drug Development Coordinator and group leader of the Anti-Tropomyosin Drug Development Group in Prof Gunning's Oncology Research Unit in the School of Medical Sciences at the University of New South Wales. She received her PhD from the Garvan Institute of Medical Research in 2000. She was awarded a prestigious National Health and Medical Research Council (NHMRC) CJ Martin Fellowship to support her postdoctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT).
Prof. Gunning has published more than 140 research papers, and his research focuses on diseases of childhood, primarily cancer and muscle damage. He completed his PhD at Monash University on gene expression in the nervous system, and then spent nine years at Stanford University working first on neuronal differentiation and then on the regulation of the genes responsible for specifying the structure of muscle. His research group discovered that tropomyosins are used to specify the spatial and temporal properties of the cell cytoskeleton in all cells of the body.
Graham Kelly, Ph.D., Novogen Executive Director and Chief Executive Officer, said, "We are privileged to have the two inventors of this drug technology join us, and provide a considerable boost to our goal of entering the clinic with a lead candidate compound in early 2015. Their intimate knowledge of the technology, combined with our drug development experience is a very strong combination that will help us in our goal of finding new and highly effective approaches to treat many of the world's most deadly cancers."
About Anti-Tropomyosin (ATM) Drugs
ATM drugs target the tropomyosin protein component of actin microfilaments. Microfilaments, along with microtubules, form the bulk of a cell's cytoskeleton, a largely invisible structure that allows the cell to communicate internally and with neighboring cells, to move, to adhere to other cells, and to divide. Drugs targeting the cytoskeleton (micro tubular component) have been among the most widely-used drugs in oncology for over 30 years and include taxes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). However, the range of tumor types sensitive to these drugs is limited and their action is not limited to cancer cells, with resulting dose-limiting toxicity involving the gut, bone marrow and nerves.
Novogen ATM drugs have been designed to target the Tm5NM1 isoform of tropomyosin specifically. To date, cell types such as melanoma and neuroblastoma that have a high degree of inherent insensitivity to anti-microtubular drugs (e.g. taxanes), have proved highly sensitive to ATM drugs.
About Novogen Limited
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website, www.novogen.com.
16-20 Edgeworth David Ave, Hornsby NSW 2077 AUSTRALIA
P.O. Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA
 Cancer Res 73, 5169-5182 (2013). Justine R. Stehn et al. A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells.
SOURCE Novogen Limited
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
Mar. 24, 2017 04:30 AM EDT Reads: 2,466
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 24, 2017 04:15 AM EDT Reads: 1,202
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Mar. 24, 2017 04:15 AM EDT Reads: 1,109
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
Mar. 24, 2017 03:30 AM EDT Reads: 3,154
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Mar. 24, 2017 03:15 AM EDT Reads: 7,914
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, provided the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” used open source attack tools that are free and available for download by anybody. Attendees learned where to find and how to operate these tools for the purpose of testing their own IT infrastructure. The...
Mar. 24, 2017 02:15 AM EDT Reads: 7,031
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Mar. 24, 2017 01:45 AM EDT Reads: 1,231
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
Mar. 24, 2017 01:30 AM EDT Reads: 3,483
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Mar. 23, 2017 11:30 PM EDT Reads: 728
SYS-CON Events announced today that Cloud Academy will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud computing technologies. Ge...
Mar. 23, 2017 11:30 PM EDT Reads: 4,359
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
Mar. 23, 2017 10:45 PM EDT Reads: 2,392
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Mar. 23, 2017 10:15 PM EDT Reads: 3,277
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Mar. 23, 2017 10:00 PM EDT Reads: 3,432
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Mar. 23, 2017 07:15 PM EDT Reads: 4,307
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Mar. 23, 2017 06:00 PM EDT Reads: 1,337